Quest PharmaTech Provides Corporate Update including Voluntary Adoption of CSA Blanket Order 51-93 to File Financial Statements and MD&A on Semi-Annual Basis
EDMONTON, Alberta, May 29, 2026 (GLOBE NEWSWIRE) -- Quest PharmaTech Inc. (TSX-V: QPT) (“Quest” or the “Company”), a Canadian based pharmaceutical company developing products to improve the quality of life through investee companies and proprietary technologies, today provided a corporate update and announced that it has filed its annual audited financial statements for the year ended January 31, 2026, Management’s Discussion and Analysis and related filings on SEDAR+ (www.sedarplus.ca). The C
EDMONTON, Alberta, May 29, 2026 (GLOBE NEWSWIRE) -- Quest PharmaTech Inc. (TSX-V: QPT) (“Quest” or the “Company”), a Canadian based pharmaceutical company developing products to improve the quality of life through investee companies and proprietary technologies, today provided a corporate update and announced that it has filed its annual audited financial statements for the year ended January 31, 2026, Management’s Discussion and Analysis and related filings on SEDAR+ (www.sedarplus.ca). The Company reported net income of $5.0 million, total liabilities of $1.3 million and total assets of $27.8 million, including a 26.6% equity interest in a Korean private company called OQPBIOM that was valued at $19.8 million as at January 31, 2026.
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.